ライフサイエンスコーパス: clinical practice

1 electivity are on their way to revolutionize clinical practice.

2 ctice advice on how to incorporate them into clinical practice.

3 erefore considered as a quality indicator of clinical practice.

4 routinely adopted for risk stratification in clinical practice.

5 f nutrition-related evaluations into routine clinical practice.

6 e level and its translational potential into clinical practice.

7 ting using a follow-up scheme that resembles clinical practice.

8 eld for the application of HIF inhibitors in clinical practice.

9 ain lung cancer screening trials rather than clinical practice.

10 quired before it can be adopted into routine clinical practice.

11 econd generation beta-lactam antibiotic into clinical practice.

12 ll with the established Roche assays used in clinical practice.

13 f RESs in patients who are representative of clinical practice.

14 mRNA delivery could fundamentally transform clinical practice.

15 wards future directions for CAA research and clinical practice.

16 d an updated systematic review to help guide clinical practice.

17 xamples, and consider their implications for clinical practice.

18 ay critical roles in both basic research and clinical practice.

19 ailure of translation of cardioprotection to clinical practice.

20 se and translation of new opportunities into clinical practice.

21 evelopmental age are an important problem in clinical practice.

22 nics, based on nurses' autonomy and scope of clinical practice.

23 d treatment strategies, and generally inform clinical practice.

24 ad range of reimplant strategies are used in clinical practice.

25 enotypic or phenotypic antifungal testing in clinical practice.

26 symptomatic aortic stenosis (AS) in routine clinical practice.

27 reting texture indices in future studies and clinical practice.

28 se trials influenced the frequency of EVT in clinical practice.

29 rther work to look at its use in the area of clinical practice.

30 eutic avenues to improve patient outcomes in clinical practice.

31 icable quantitative BKV DNA load cutoffs for clinical practice.

32 selection, but is not yet a regular part of clinical practice.

33 allow identification of patient endotypes in clinical practice.

34 a reasonable alternative to other stents in clinical practice.

35 atelet therapy should not be used in routine clinical practice.

36 ly lead to major discoveries and advances in clinical practice.

37 ranslation of autism genetics knowledge into clinical practice.

38 ch to common dilemmas encountered in routine clinical practice.

39 ional chemotherapy regimens are warranted in clinical practice.

40 between the proposed tool and gold-standard clinical practice.

41 have contributed to inconsistent adoption in clinical practice.

42 pportunities for translatory applications in clinical practice.

43 king the evolution of lung cancers might aid clinical practice.

44 udies and could feasibly be implemented into clinical practice.

45 ing metallic stent in the context of routine clinical practice.

46 lood highlighting their potential utility in clinical practice.

47 ical Oncology, to patients seen in their own clinical practice.

48 n when selecting the most suitable method in clinical practice.

49 turing a more holistic picture of effects in clinical practice.

50 r generator-eluted (99m)Tc-NaTcO4 in routine clinical practice.

51 lated macular degeneration (nAMD) in routine clinical practice.

52 al diagnosis of childhood TB in research and clinical practice.

53 underrecognized but not uncommon problem in clinical practice.

54 erature concerning Fahr syndrome in terms of clinical practice.

55 roduction of the C inhibitor eculizumab into clinical practice.

56 itation to be translated, quite easily, into clinical practice.

57 atients who are eligible for this therapy in clinical practice.

58 ngly support the implementation of IQ-CSF in clinical practice.

59 ations and limitations of genomic testing in clinical practice.

60 er trials and even fewer have become part of clinical practice.

61 e accurate quantification to enhance current clinical practice.

62 support RV failure have been introduced into clinical practice.

63 ractive radiotracer for infection imaging in clinical practice.

64 linical trials and those observed in routine clinical practice.

65 rpretations of progression on OCT imaging in clinical practice.

66 r randomised trials that are closer to usual clinical practice.

67 clinical trials and even fewer have reached clinical practice.

68 This practice is being introduced into clinical practice.

69 th a low number of SRs observed in real-life clinical practice.

70 nitiatives to improve guideline adherence in clinical practice.

71 ed when making conclusions regarding CDRs in clinical practice.

72 fects of an oral health checklist in routine clinical practice.

73 le sclerosis are widely used in research and clinical practice.

74 izing the burden on health care resources in clinical practice.

75 ajor bleeding in patients treated in routine clinical practice.

76 hy SDM has not been implemented into routine clinical practice.

77 Vitreoretinal clinical practice.

78 s of interest influence medical research and clinical practice.

79 CVD death, but is not routinely measured in clinical practice.

80 needed to determine its role in research and clinical practice.

81 OPG by various dental practitioners in their clinical practice.

82 erse outcomes of off-label use of TAVR in US clinical practice.

83 different forms of HUS may prove helpful in clinical practice.

84 rease the value of HCC screening programs in clinical practice.

85 tumor cells from peripheral venous blood in clinical practice.

86 ional, prospective study under conditions of clinical practice.

87 re of translation from medical research into clinical practice.

88 beyond the clinical trial sites into general clinical practice.

89 ntions that translate research evidence into clinical practice.

90 ople, who are also underdiagnosed in routine clinical practice.

91 eumonia in young children as part of routine clinical practice.

92 nsider when incorporating these results into clinical practice.

93 biologic therapies for psoriasis in routine clinical practice.

94 ide guidance on the appropriate use of CE in clinical practice.

95 porting yearly benefit-risk re-evaluation in clinical practice.

96 parameters should be sufficiently robust for clinical practice.

97 therapy, and how this could be translated to clinical practice.

98 he lack of data showing incremental value in clinical practice.

99 unction and to translate that knowledge into clinical practice.

100 ortality and should be favored over eFick in clinical practice.

101 ould incorporate shared decision making into clinical practice.

102 hemophilia B will likely continue to change clinical practice.

103 ntemporary clinical trials that have changed clinical practice.

104 ches have been validated and translated into clinical practice.

105 key step to translating these findings into clinical practice.

106 elpful in assessing patients with dry eye in clinical practice.

107 ght some challenges in bridging research and clinical practice.

108 ion in the dlPFC that can be translated into clinical practice.

109 oinfected patients initiating HCV therapy in clinical practice.

110 icient information about tCS to inform their clinical practices.

111 ive medical record review was conducted at 3 clinical practices (1 academic and 2 private).

112 To increase consistency in clinical practice, a recommendation is made to modify th

113 our recommendations can provide guidance for clinical practice, ACP policy, and research.

114 d to verify this hypothesis commonly used in clinical practice although it has not been prospectively

115 need to be substantially lower ($9669 for US clinical practice and $6780 for trial participants), or

116 to discriminate between biologics to inform clinical practice and decision making.

117 The secondary aim is to reflect on our clinical practice and discuss strategies to build a succ

118 d severity assessments that are feasible for clinical practice and epidemiological research.

119 d be used to inform therapeutic decisions in clinical practice and for the design of clinical trials.

120 llar ataxia are frequently found together in clinical practice and form a heterogeneous group of dege

121 ed to translate these promising results into clinical practice and improve motor rehabilitation outco

122 an change how novel therapeutics are used in clinical practice and inform patient and clinician decis

123 DIBH PET/CT technique is feasible in routine clinical practice and is more sensitive for quantitative

124 These indicators present challenges for clinical practice and national nutrition surveys, and of

125 ung cancer treatment remains a challenge for clinical practice and new therapeutic approaches are urg

126 neuroimaging has yet to substantially impact clinical practice and public health.

127 associated with lower surveillance rates in clinical practice and represent potential intervention t

128 ld complement macrowear assessment in dental clinical practice and research and could assist in the e

129 ssment of atopic sensitization is pivotal to clinical practice and research.

130 natural history, which are crucial to inform clinical practice and research.

131 CF and discusses the implications for future clinical practice and research.

132 associated with mortality and (2) summarize clinical practice and risk factors in the subgroup of pa

133 risk score can be easily calculated in daily clinical practice and strongly correlated with mortality

134 lay in the implementation of biomarkers into clinical practice and the association with severe sequel

135 entation of therapeutic patient education in clinical practice and the design of comprehensive self-m

136 end points to evaluate efficacy of drugs in clinical practice and trials, exist.

137 tios as a biomarker of amyloid deposition in clinical practice and trials.

138 biomarkers and/or amyloid PET assessment in clinical practice and trials.

139 dies have been performed under conditions of clinical practice and with a sufficiently long observati

140 CEA informs the identification of high-value clinical practices and can be used to evaluate preventat

141 hat 1) reveal fundamental biology, 2) inform clinical practice, and 3) deliver new therapeutic target

142 for translating basic science research into clinical practice, and 77.2% of all participants believe

143 he role of established biomarkers in routine clinical practice, and a range of other circulating nove

144 pressure monitoring that is not feasible in clinical practice, and as such limits the generalizabili

145 This information could otherwise support clinical practice, and promote value-based decision-maki

146 This study was set in a glaucoma clinical practice, and the dataset included 3490 scans f

147 Recent changes in clinical practice are associated with reductions in pret

148 fibrillation, but large-scale evaluations in clinical practice are limited.

149 anglioside antibodies have long been used in clinical practice as diagnostic serum biomarkers, and as

150 This distinction has enhanced clinical practice as direct determination of LGI1 and CA

151 inicians should be aware of these changes in clinical practice as well as the diverse presentation of

152 isease severity index may have relevance for clinical practice, as well as for selecting appropriate

153 , and extranodal involvement, and review our clinical practice based on available evidence in adminis

154 kelihood of success and enhance the fit with clinical practice Based on existing intervention develop

155 ess (WT) measurements as obtained by routine clinical practice between echocardiography and cardiac m

156 surprisingly limited evidence to inform best clinical practice both at the time of diagnosis and duri

157 This finding could impact clinical practice, but has not yet been validated in oth

158 farction and myocardial injury are common in clinical practice, but long-term consequences are uncert

159 cognition of cardiac amyloidosis in everyday clinical practice, but the diagnosis continues to be mad

160 In a national, contemporary clinical practice cohort of unselected patients, improve

161 nated and followed up for 21 days under good clinical practice conditions.

162 on of information about appropriate use with clinical practice could improve adherence, and thereby r

163 with idiopathic pulmonary fibrosis (IPF) in clinical practice could participate in the INPULSIS tria

164 In clinical practice, delays in obtaining culture results i

165 Nearly half of the newly detected AMAs in clinical practice does not lead to a diagnosis of PBC.

166 As this technology moves into general clinical practice, evaluation of the health status outco

167 stems, a paucity of digital data on everyday clinical practice, financial subsidies and incentives th

168 that MRD detection may soon be applicable in clinical practice for most patients with lymphoma.

169 ould be fully automated for integration into clinical practice for point-of-care or molecular detecti

170 Hence ST2 may be helpful in clinical practice for prognostication and treatment moni

171 d barriers to adoption of teledermatology in clinical practice for the diagnosis of skin cancer?

172 Given 25(OH)D is modifiable in clinical practice, future studies should consider the li

173 mine the incremental cost-effectiveness of a clinical practice guideline (CPG) compared with "usual c

174 Purpose To update a clinical practice guideline (CPG) for the empirical mana

175 This clinical practice guideline addresses six questions rela

176 Dermatology clinical practice guideline authors received sizable ind

177 To determine whether a novel, 2-part, clinical practice guideline could decrease the rates of

178 s performed to determine the effect of a new clinical practice guideline on blood culture practices i

179 This study is applicable to clinical practice guideline panels drafting recommendati

180 ancer: American Society of Clinical Oncology Clinical Practice Guideline published on May 31, 2016.

181 This clinical practice guideline recommended by the Internati

182 tered only when indicated based on published clinical practice guidelines and timed such that a bacte

183 Clinical practice guidelines are systematically develope

184 The ASCO guideline approval body, the Clinical Practice Guidelines Committee, approved the fin

185 ly vaccinated for HPV may be considered when clinical practice guidelines for cervical cancer screeni

186 The clinical practice guidelines for heart failure recommend

187 and family-centered care to revise the 2007 Clinical Practice Guidelines for support of the family i

188 ials, systematic reviews, meta-analyses, and clinical practice guidelines from 2012 through July 2016

189 ed in systematic reviews and integrated into clinical practice guidelines in several countries.

190 These data suggest that adherence to clinical practice guidelines is particularly challenging

191 s part of a larger effort to update existing clinical practice guidelines on cholesterol, blood press

192 This document provides evidence-based clinical practice guidelines on the use of mechanical ve

193 veloped the science of producing trustworthy clinical practice guidelines pioneered by investigators

194 a policy and set of procedures for endorsing clinical practice guidelines that have been developed by

195 of procedures for endorsing and/or adapting clinical practice guidelines that have been developed by

196 s drafting recommendations, physicians using clinical practice guidelines to inform patient care, and

197 ublished translational and clinical studies, clinical practice guidelines, and expert opinion/stateme

198 eceived by physicians who author dermatology clinical practice guidelines, compare disclosure stateme

199 included 24 more recent publications: three clinical practice guidelines, eight systematic reviews,

200 alitative research to enhance development of clinical practice guidelines, using recent guidelines fo

201 ased strategies for effectively implementing clinical practice guidelines.

202 d on sex and height) has been recommended in clinical practice guidelines.

203 ied among physicians who develop dermatology clinical practice guidelines.

204 stitute of Medicine's tenets for trustworthy clinical practice guidelines.

205 confirmatory testing strategy, in line with clinical practice guidelines.

206 cancer screening is recommended in multiple clinical practice guidelines.

207 but the generalizability of those results in clinical practice has been challenged.

208 are from model organisms, and translation to clinical practice has been limited.

209 ctices and high copays, and use of PSCK9i in clinical practice has been low.

210 e implementation of RNAi technology into the clinical practice has been significantly postponing due

211 rdioprotection beyond that by reperfusion to clinical practice has to date been disappointing.

212 ial replacement technique (MRT) research and clinical practice have raised ethical concerns worldwide

213 decided that four areas of current oncology clinical practice have serious, unmet health information

214 fore translating these findings into routine clinical practice, however, several challenges loom.

215 ructure and function, pulmonary research and clinical practice in obstructive lung disease, and drug

216 bility of retinal diagnosis for research and clinical practice in ophthalmology.

217 erest with the bold promise to revolutionize clinical practice in psychiatry paralleling similar deve

218 ommended in guidelines and currently used in clinical practice in several countries to predict outcom

219 tuberculosis diagnosis with the realities of clinical practice in small villages and low-resource set

220 er 10 y, highlighting the major challenge in clinical practice in the rehabilitation of dental implan

221 and facilitate its implementation in routine clinical practice in various settings and institutions w

222 ity to translate SPRINT results into routine clinical practice, in which measurement of BP is typical

223 An algorithm that follows clinical practice, including patient history, clinical,

224 r image standardization is likely to improve clinical practice, information exchange, electronic heal

225 use of ambulatory hemodynamic monitoring in clinical practice is associated with lower HFH and compr

226 e potential application of this knowledge to clinical practice is discussed, along with a theory unif

227 for patients, but successful translation to clinical practice is hindered by the lack of thorough pr

228 reatment goals are achieved in international clinical practice is unknown.

229 urveillance imaging is commonly performed in clinical practice, its ability to identify asymptomatic

230 Despite widespread use of MgSO4 in clinical practice, its effects on adult offspring are no

231 There is no evidence that, in clinical practice, lansoprazole can treat or prevent inc

232 orts to integrate molecular information into clinical practice, new approaches to early detection, an

233 may not provide a comprehensive resource for clinical practice or "big data" research.

234 any, have been developed for use in routine clinical practice or adopted for use in research studies

235 nts' admission MMI score and end of Year one clinical practice outcomes (OSCE and mentor grading).

236 In the base case, using US clinical practice patients with atherosclerotic cardiova

237 Clinical practice performance data can inform ongoing be

238 On the basis of substantive ethics, clinical practice, policy, and other concerns articulate

239 In routine clinical practice, prescribed NOAC doses are often incon

240 In research studies and clinical practice, quality of measurement is more import

241 or patients admitted to hospital for routine clinical practice rather than for isolation purpose.

242 This Statement is not intended to provide clinical practice recommendations on any disease in whic

243 suggestions, considerations, or contemporary clinical practice recommendations.

244 s emergent approach to health conception and clinical practice reconfigures conventional historical u

245 , we address common questions encountered in clinical practice regarding etiology, clinical presentat

246 ness and durability of protection in routine clinical practice remain.

247 cessfully incorporating genetic testing into clinical practice requires (1) recognizing when inherite

248 s delineated for 1998 through 2014 using the Clinical Practice Research Datalink (CPRD) and linked to

249 ronic health records from the United Kingdom Clinical Practice Research Datalink (CPRD) from 1 Januar

250 dy, we included all patients registered at a Clinical Practice Research Datalink (CPRD) practice betw

251 th records of 4 million individuals from the Clinical Practice Research Datalink (CPRD), a cohort tha

252 udy population was derived from the UK-based Clinical Practice Research Datalink (CPRD).

253 and general practice from the United Kingdom Clinical Practice Research Datalink database.

254 linked population-based healthcare datasets (Clinical Practice Research Datalink General Practice OnL

255 ole, or pantoprazole from the United Kingdom Clinical Practice Research Datalink to determine whether

256 survival analysis on all patients within the Clinical Practice Research Datalink who had undergone to

257 2012, was formed using the United Kingdom's Clinical Practice Research Datalink.

258 logy of SJS/TEN using data from the UK-based Clinical Practice Research Datalink.

259 h population and general practices in the UK Clinical Practice Research Datalink.

260 We provide recommendations for education, clinical practice, research, and policy initiatives that

261 gressed after 5 years of annual testing in a clinical practice scenario.

262 In clinical practice, seizures in patients with Alzheimer's

263 INTERPRETATION: In this clinical practice setting, rivaroxaban in patients with

264 and therapeutic pathways that we use in our clinical practice setting.

265 5: Clinicians incorporating EBTs into their clinical practice should follow up patients prospectivel

266 s embarking on incorporating EBTs into their clinical practice should have a comprehensive knowledge

267 Literature of clinical practice shows evidence of wide variability in

268 t provide measures of axonal injury to guide clinical practice.Significance: This detailed preclinica

269 we argue strongly for a flexible approach in clinical practice that takes into consideration the high

270 ilon3/epsilon4, and brings into personalized clinical practice the immune benefits expected from omeg

271 In clinical practice, the current diagnostic methods, such

272 eters are to be successfully introduced into clinical practice, the ease of use, safety and effective

273 Owing to their success in clinical practice, the prevalence of cardiovascular impl

274 Despite more than a century of use in clinical practice, the prototypic binding site for this

275 itiatives from the research environment into clinical practice-the World Health Organization (WHO) ha

276 ase and, although increasingly recognized in clinical practice, there is a lack of widely accepted di

277 In clinical practice, there is still widespread uncertainty

278 RELEVANCE TO CLINICAL PRACTICE: This paper highlights that if multi-u

279 The system can be implemented in clinical practice to allocate resources and allow the co

280 m mouse models with common observations from clinical practice to comprehensively review melanocytic

281 e whether depressive symptoms can be used in clinical practice to discriminate for LB.

282 le coronary stents have been introduced into clinical practice to improve the outcomes of patients tr

283 ion after circulatory death (DCD) is current clinical practice to increase the donor pool.

284 ring loss in mature animals, it has not been clinical practice to sequence ATOH1 in people with deafn

285 mong immunosuppressive approaches used in in clinical practice today, yet an optimal therapeutic dose

286 Although OCT has been adopted widely in clinical practice, uncertainty remains concerning its op

287 In this clinical practice update, available evidence and expert

288 The Clinical Practice Updates Committee of the American Gast

289 The Clinical Practice Updates Committee of the American Gast

290 round who present with pulmonary symptoms in clinical practice, use of background-specific spirometry

291 ors and may improve models currently used in clinical practice; validation of FABP1 as a clinical pre

292 fe' respiratory allergen immunotherapy (AIT) clinical practice was conducted in France, Germany and S

293 mmunity landscape and may become relevant in clinical practice, we aim to reconcile differing views a

294 ed on laboratory tests commonly performed in clinical practice, we aimed to develop a new model to pr

295 To translate the findings from SPRINT to clinical practice, we developed prediction models to tai

296 This has high relevance in clinical practice where complete datasets are difficult

297 Prevention), but the much-needed changes in clinical practice will be facilitated by a better unders

298 of molecular imaging of coronary plaque into clinical practice will depend on overcoming major hurdle

299 This finding could change established clinical practice, with a clear economic benefit.

300 me analysis method, which is already used in clinical practice, with electrochemical principles.